Literature DB >> 6966221

Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy.

P Coassolo, M Valentin, M Bourdeaux, C Briand.   

Abstract

The binding of methotrexate (MTX) and citrovorum factor (CF) to human serum albumin (HSA) was investigated. The affinity constant for MTX was 820 M-1, with 2 binding sites, and for CF 2340 M-1, with 1.5 binding sites. MTX and CF, which are used together in high dose therapy, compete for HSA binding. Competition for HSA binding between MTX and adriamycin, bleomycin and cyclophosphamide, drugs often used in association with MTX in cancer chemotherapy, was also demonstrated. The clinical importance of such competition depends on the drug/protein concentration ratio which is extremely variable.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966221     DOI: 10.1007/BF00562620

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

2.  The use of macromolecules as carriers of antitumor drugs.

Authors:  M Szekerke; J S Driscoll
Journal:  Eur J Cancer       Date:  1977-06       Impact factor: 9.162

3.  Microcalorimetric studies on the binding of some benzodiazepine derivatives to human serum albumin.

Authors:  P Coassolo; M Sarrazin; J C Sari; C Briand
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

4.  Microcalorimetric method to determine competitive binding. Action of a psychotropic drug (dipotassium chlorazepate) on L-tryptophan . human serum albumin complex.

Authors:  P Coassolo; C Briand; M Bourdeaux; J C Sari
Journal:  Biochim Biophys Acta       Date:  1978-02-01

Review 5.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

6.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

7.  Continuous infusion of methotrexate in children with acute leukemia.

Authors:  I Djerassi; S Farber; E Abir; W Neikirk
Journal:  Cancer       Date:  1967-02       Impact factor: 6.860

8.  Antitumor drug-protein interactions. Binding of 1-beta-D-arabinofuranosyl cytosine to albumin and chemically modified albumin.

Authors:  M Szekerke; M Horváth; F Hudecz
Journal:  Arzneimittelforschung       Date:  1979

9.  Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols.

Authors:  I D Goldman; V Gupta; J C White; S Loftfield
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

10.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity.

Authors:  A J Weiss; R W Manthel
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

View more
  3 in total

1.  Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Authors:  D J Grimes; M R Bowles; J A Buttsworth; D B Thomson; P J Ravenscroft; P F Nixon; R F Whiting; S M Pond
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

Review 2.  Breast cancer: insights in disease and influence of drug methotrexate.

Authors:  Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal:  RSC Med Chem       Date:  2020-05-28

Review 3.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.